3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Recruiting
3
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Gynecologic
2
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
3
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
65
Nivolumab
58
Magnetic Resonance Spectroscopy
53
enzalutamide
39
Abiraterone Acetate
37
Radiosurgery
36
Gemcitabine
35
Specimen Handling
32
Radiotherapy
32
Ipilimumab
32
Androgen Antagonists
32
Prednisone
31
apalutamide
28
Cisplatin
28
Docetaxel
27
Leuprolide
26
atezolizumab
25
Carboplatin
25
durvalumab
23
cabozantinib
23
darolutamide
20
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
19
olaparib
18
Goserelin
17
Radiation
16
Gonadotropin-Releasing Hormone
16
Biopsy
16
gallium 68 PSMA-11
15
Pluvicto
15
avelumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
AZD5305
×
Genitourinary
×
Clear all
NCT05367440
2026-06-01
PETRANHA
AstraZeneca
Phase 1/2
Active not recruiting
174 enrolled
NCT06120491
2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3
Active not recruiting
1,889 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled